Lumonus, the company behind Lumonus AI, has announced a partnership with Memorial Sloan Kettering Cancer Center (MSK), a leading cancer treatment and research center. Their platform helps manage radiation therapy workflows and automatically plan treatments.
Through this partnership, Lumonus will use and further develop MSK’s ECHO technology in its platform. They will also work together on research to improve automated radiation therapy treatment planning.
“Over the last twenty years, automated planning systems have demonstrated real clinical value — improving dosimetric quality, consistency and efficiency across multiple studies. But scaled adoption has remained elusive. The core challenge is that each plan must navigate complex, competing constraints that are specific to the individual patient, and there has been no robust way to consistently produce the optimal solution and confirm it meets the treating physician’s clinical intent,” said Tim Fox, Chief Product Officer at Lumonus.
“Our strategic collaboration with MSK represents a decisive step forward. The next generation of planning automation requires a mathematically principled solver capable of consistently delivering the optimal plan, working in concert with intelligent review tools that capture the nuanced clinical judgement of physicians in real-world practice. Together with MSK, we are building the infrastructure to move automation from promising results to scaled, routine deployment.”
MSK’s ECHO system uses advanced math to create radiation therapy treatment plans from the ground up. It follows set rules and conditions to make sure the plans are accurate and effective.
It has been developed and used in real clinical settings for nearly 10 years and is backed by a lot of research. Because of this, ECHO is considered one of the most reliable methods for automated treatment planning in radiation oncology.
“Our goal in developing ECHO has always been to improve the quality, consistency, and efficiency of radiation therapy treatment planning,” said Masoud Zarepisheh, PhD, Associate Attending and lead developer of ECHO at MSK. “Our collaboration with Lumonus creates an important opportunity to combine clinically validated optimization methods with modern workflow tools and help expand the adoption of automated treatment planning in radiation oncology.”
Lumonus is a healthcare technology company that has built Lumonus AI for radiation oncology. It works with leading cancer centers to improve how cancer treatment is planned and managed using AI.
The platform helps automate important tasks, making treatment faster, improving quality, and reducing paperwork. Lumonus operates in the United States, Australia, and Europe.
Read More- Atlas raises $6 million in round led by Accel
